Key result
Deferral of revascularization based on FFR ≥0.75 in patients with ACS and moderate coronary stenoses was associated with low event rates at 12 months, including a 15% TVR rate vs 9% without ACS.
Why the study?
Does deferral of revascularization based on FFR prevent adverse clinical events in patients with acute coronary syndromes and moderate coronary lesions?
Cohort (n=111)
Does deferral of revascularization based on FFR prevent adverse clinical events in patients with acute coronary syndromes and moderate coronary lesions?
Absolute Event Rate: 15% vs 9%
Deferring revascularization for moderate coronary lesions based on FFR ≥ 0.75 in patients with ACS is associated with low event rates at 1 year, similar to patients without ACS.
May support FFR-guided deferral in selected ACS; leaves open need for prospective trials before practice change.
OBJECTIVES: To determine the outcome of consecutive patients with and without acute coronary syndromes (ACS) in whom revascularization was deferred on the basis of fractional flow reserve (FFR). BACKGROUND: FFR < 0.75 correlates with ischemia on noninvasive tests and deferral of treatment on the basis of FFR is associated with low event rates in selected populations. Whether these low event rates apply to patients undergoing assessment of moderate stenoses in association with an ACS is not known and is an important clinical question. METHODS: Retrospective analysis and 12 month follow-up of consecutive, moderate (50-70%) de novo coronary lesions assessed with FFR. RESULTS: Revascularization was deferred in 120 lesions (111 patients) with FFR > or = 0.75. ACS was present in 35 patients (40 lesions). The clinical, angiographic and coronary hemodynamic characteristics of patients with and without ACS were similar. Among the 35 patients with ACS, there were 3 deaths, 1 MI, and 6 target vessel revascularizations (TVRs) (15% of lesions). Among the 76 patients without ACS, there were 5 deaths, 1 MI, and 7 TVR's (9% of lesions). CONCLUSIONS: Deferral of revascularization based on FFR in patients with ACS and moderate coronary stenoses is associated with acceptable and low event rates at 1 year.
No takes yet. Share an insight, caveat, or question.
Fischer et al. (2006) conducted a cohort in Acute coronary syndromes and moderate coronary lesions (n=111). Acute coronary syndromes (ACS) vs. Without acute coronary syndromes was evaluated on Target vessel revascularization (TVR). Deferral of revascularization based on FFR ≥0.75 in patients with ACS and moderate coronary stenoses was associated with low event rates at 12 months, including a 15% TVR rate vs 9% without ACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: